These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 225005)

  • 1. Absence of carcinoembryonic antigen-like material in mesothelioma: an immunohistochemical differentiation from other lung cancers.
    Wang NS; Huang SN; Gold P
    Cancer; 1979 Sep; 44(3):937-43. PubMed ID: 225005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
    Holden J; Churg A
    Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.
    Whitaker D; Sterrett GF; Shilkin KB
    Pathology; 1982 Jul; 14(3):255-8. PubMed ID: 6290965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma.
    Shijubo N; Honda Y; Fujishima T; Takahashi H; Kodama T; Kuroki Y; Akino T; Abe S
    Eur Respir J; 1995 Mar; 8(3):403-6. PubMed ID: 7789485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma.
    Sheibani K; Shin SS; Kezirian J; Weiss LM
    Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The usefulness of the quantitative evaluation of the plasma levels of the carcinoembryonic antigen (CEA) in patients with respiratory neoplasms (author's transl)].
    Richart C; Ruibal A; Monné J
    Med Clin (Barc); 1979 Oct; 73(6):239-41. PubMed ID: 232738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung.
    Tron V; Wright JL; Churg A
    Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas.
    Popper H; Wirnsberger G; Hoefler H; Denk H
    Cancer Detect Prev; 1987; 10(3-4):167-74. PubMed ID: 2436780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothelioma, and reactive mesothelium.
    Marshall RJ; Herbert A; Braye SG; Jones DB
    J Clin Pathol; 1984 Nov; 37(11):1215-21. PubMed ID: 6094617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A scanning electron microscopic study of diffuse mesothelioma and some lung carcinomas.
    Dionne GP; Wang NS
    Cancer; 1977 Aug; 40(2):707-15. PubMed ID: 196741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
    Lucas JG; Tuttle SE
    J Surg Oncol; 1987 May; 35(1):30-4. PubMed ID: 2437407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
    Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
    Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of fifty-four cases, with ultrastructural correlations.
    Said JW; Nash G; Tepper G; Banks-Schlegel S
    Hum Pathol; 1983 Jan; 14(1):70-6. PubMed ID: 6187653
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
    Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
    Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.